Septic shock.
Shenep
J L
JL
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002675:Child, Preschool; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000009:adverse effects / Q000502:physiology*; D007378:Interleukins / Q000502:physiology; D008050:Lipid A / Q000031:analogs & derivatives; D009270:Naloxone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009569:Nitric Oxide / Q000502:physiology; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors; D012772:Shock, Septic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators; D007378:Interleukins; D008050:Lipid A; D009292:Narcotic Antagonists; D011971:Receptors, Immunologic; D014409:Tumor Necrosis Factor-alpha; C048071:endotoxin receptor; D009569:Nitric Oxide; D009270:Naloxone